Johnson Matthey completes sale of its Diagnostic Services business

Johnson Matthey Plc (LON:JMAT), has announced that, further to the announcement on 3^rd May 2023, it has completed the sale of its Diagnostic Services business on 29^th September 2023 in accordance with the terms of the sale agreement entered into between JM and Sullivan Street Partners for a consideration of £55 million.

Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, we improve the performance, function and safety of our customers’ products.

Share on:

You might also enjoy reading Johnson Matthey issues pre-close update and reclassifies Catalyst Technologies

Written by: Amilia Stone

Latest Company News

Johnson Matthey issues pre-close update and reclassifies Catalyst Technologies

October 9, 2025

Johnson Matthey has confirmed that Catalyst Technologies, following its agreed sale to Honeywell, will be reported as a discontinued operation for 2025/26. In its pre-close update for the half year to 30 September 2025, the group expects strong growth in underlying operating profit, supported by efficiency gains and robust trading in PGM Services.

Johnson Matthey appoints Richard Pike as Chief Financial Officer Designate

February 10, 2025

Johnson Matthey plc appoints Richard Pike as Chief Financial Officer Designate, effective immediately, ensuring a smooth transition before April 2025.

Johnson Matthey Plc hosting PGM Services seminar for investors and analysts today

June 27, 2024

Join Johnson Matthey plc (LON:JMAT) as they host a PGM Services seminar, revealing how PGM Services drive the net zero transition and unlock growth opportunities.

Johnson Matthey Plc to sell Medical Device Components business for $700 million

March 20, 2024

Johnson Matthey Plc (LON:JMAT) has signed an agreement to sell its Medical Device Components business to Montagu Private Equity for US$700 million (£550 million).